NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib

Therapy of cutaneous T cell lymphoma (CTCL) is complicated by a distinct resistance of the malignant T cells towards apoptosis that can be caused by NRAS mutations in late-stage patients. These mutations correlate with decreased overall survival, but sensitize the respective CTCL cells towards MEK-i...

Descripción completa

Detalles Bibliográficos
Autores principales: KieΔling, Michael K., Nicolay, Jan P., Schlör, Tabea, Klemke, Claus-Detlev, Süss, Dorothee, Krammer, Peter H., Gülow, Karsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542218/
https://www.ncbi.nlm.nih.gov/pubmed/28537899
http://dx.doi.org/10.18632/oncotarget.17669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542218/
https://www.ncbi.nlm.nih.gov/pubmed/28537899
http://dx.doi.org/10.18632/oncotarget.17669

Ejemplares similares